Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Psyence Biomedical Ltd. Common Shares (PBM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PBM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -16.21% | Avg. Invested days 103 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.86M USD | Price to earnings Ratio 0.12 | 1Y Target Price - |
Price to earnings Ratio 0.12 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.15 | 52 Weeks Range 2.94 - 466.80 | Updated Date 06/29/2025 |
52 Weeks Range 2.94 - 466.80 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 41.76 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.2% | Return on Equity (TTM) - |
Valuation
Trailing PE 0.12 | Forward PE - | Enterprise Value 3432164 | Price to Sales(TTM) - |
Enterprise Value 3432164 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 3.35 | Shares Outstanding 583263 | Shares Floating 71171 |
Shares Outstanding 583263 | Shares Floating 71171 | ||
Percent Insiders 0.48 | Percent Institutions 11.13 |
Upturn AI SWOT
Psyence Biomedical Ltd. Common Shares
Company Overview
History and Background
Psyence Biomedical Ltd. is a biotechnology company focused on developing psychedelic medicines for the treatment of mental health conditions and other nervous system disorders. It was founded with the goal of leveraging scientific research to create innovative therapies.
Core Business Areas
- Drug Development: Focuses on the research and development of psychedelic-based pharmaceuticals.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Intellectual Property: Develops and protects its intellectual property portfolio related to psychedelic therapies.
Leadership and Structure
The company's leadership team includes experienced scientists, clinicians, and business executives. Its organizational structure is designed to support its research and development activities.
Top Products and Market Share
Key Offerings
- PSCI-101: A psilocybin-based drug candidate being developed for the treatment of adjustment disorder and other mental health conditions. Market share data is currently limited as the drug is in the clinical trial phase. Competitors include companies developing similar psilocybin-based therapies, such as COMPASS Pathways and MindMed.
Market Dynamics
Industry Overview
The psychedelic medicine industry is rapidly evolving, driven by increasing recognition of the potential therapeutic benefits of psychedelic compounds. There is growing interest in psychedelic-assisted therapy for conditions such as depression, anxiety, and PTSD.
Positioning
Psyence Biomedical Ltd. is positioned as a research-driven company focused on developing evidence-based psychedelic therapies. Its competitive advantage lies in its scientific expertise and focus on specific unmet medical needs.
Total Addressable Market (TAM)
The TAM for psychedelic therapies is estimated to be in the billions of dollars, with projections varying based on market penetration and regulatory approvals. Psyence is positioned to capture a segment of this TAM through its drug development efforts.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise
- Focus on evidence-based medicine
- Proprietary drug development platform
- Experienced management team
Weaknesses
- Early stage of development
- Limited financial resources
- Regulatory uncertainty
- High risk of clinical trial failures
Opportunities
- Growing acceptance of psychedelic therapies
- Potential for breakthrough therapies
- Partnerships with leading research institutions
- Expansion into new therapeutic areas
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Negative public perception
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- CMPS
- MMEDF
- ATAI
Competitive Landscape
Psyence Biomedical Ltd. competes with other companies developing psychedelic therapies. It has a focus on specific mental health conditions and a research-driven approach. It is a much smaller competitor with CMPS.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by expansion of R&D activities and securing funding.
Future Projections: Future growth is projected to be driven by successful clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for PSCI-101 and securing partnerships with research institutions.
Summary
Psyence Biomedical Ltd. is an early-stage biotech company pursuing psychedelic therapies for mental health. The company's strength lies in its research focus and experienced team, but it faces challenges related to funding, regulation, and competition. Successful clinical trial outcomes will be critical for future growth. It is significantly smaller than its competitors, with limited market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Financial news sources
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Psyence Biomedical Ltd. Common Shares
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2024-01-25 | CEO & Director Dr. Neil Maresky M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.psyencebiomed.com |
Full time employees 12 | Website https://www.psyencebiomed.com | ||
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.